Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of the mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Patients With Previously Treated Glioblastoma Multiforme

NCT02619864 is registered in ClinicalTrials.gov with Canadian Cancer Trials Group as lead sponsor.

NCT NCT02619864
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02619864 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of the mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Patients With Previously Treated Glioblastoma Multiforme
Lead sponsor
Canadian Cancer Trials Group
Phase
Phase 1
Overall status
Completed
Start date
December 22, 2016
Completion date
February 25, 2020
Enrollment
15 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme